BioCryst Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	845.82	450.71	331.41	270.83	157.17
Other Revenue	29.02	-	-	-	-
Revenue	874.84	450.71	331.41	270.83	157.17
Revenue Growth (YoY)	94.10%	36.00%	22.37%	72.31%	782.38%
Cost of Revenue	19.08	185.92	216.65	259.89	216.07
Gross Profit	855.76	264.79	114.76	10.94	-58.9
Selling, General & Admin	348.65	266.07	213.54	159.37	118.82
Research & Development	166.13	-	-	-	-
Operating Expenses	514.77	266.07	213.54	159.37	118.82
Operating Income	340.99	-1.28	-98.78	-148.44	-177.72
Interest Expense	-78.87	-98.52	-108.24	-99.09	-59.29
Interest & Investment Income	10.67	14.75	15.78	5.13	0.06
Currency Exchange Gain (Loss)	-0.15	-0.64	-1.04	-1.98	-0.7
Other Non Operating Income (Expenses)	12.09	-	-	-	-
EBT Excluding Unusual Items	284.72	-85.69	-192.28	-244.38	-237.65
Merger & Restructuring Charges	-	-1.26	-3.38	-	-
Gain (Loss) on Sale of Investments	-	-	-	-	0
Asset Writedown	-	-	-1.55	-	-
Other Unusual Items	-17.33	-	-29.02	-	55.84
Pretax Income	267.39	-86.95	-226.23	-244.38	-181.81
Income Tax Expense	3.53	1.93	0.31	2.73	2.25
Net Income	263.86	-88.88	-226.54	-247.12	-184.06
Net Income to Common	263.86	-88.88	-226.54	-247.12	-184.06
Shares Outstanding (Basic)	210	207	192	186	179
Shares Outstanding (Diluted)	219	207	192	186	179
Shares Change (YoY)	5.75%	7.54%	3.38%	3.79%	7.08%
EPS (Basic)	1.26	-0.43	-1.18	-1.33	-1.03
EPS (Diluted)	1.21	-0.43	-1.18	-1.33	-1.03
Free Cash Flow	-	-53.14	-97.31	-163.2	-144.54
Free Cash Flow Per Share	-	-0.26	-0.51	-0.88	-0.81
Gross Margin	97.82%	58.75%	34.63%	4.04%	-37.48%
Operating Margin	38.98%	-0.28%	-29.81%	-54.81%	-113.07%
Profit Margin	30.16%	-19.72%	-68.36%	-91.25%	-117.11%
Free Cash Flow Margin	-	-11.79%	-29.36%	-60.26%	-91.97%
EBITDA	342.32	1.73	-95.91	-146.18	-176.83
EBITDA Margin	39.13%	0.39%	-28.94%	-53.98%	-112.51%
D&A For EBITDA	1.33	3.01	2.87	2.25	0.89
EBIT	340.99	-1.28	-98.78	-148.44	-177.72
EBIT Margin	38.98%	-0.28%	-29.81%	-54.81%	-113.07%
Effective Tax Rate	1.32%	-	-	-	-
Revenue as Reported	874.84	-	-	-	-
Advertising Expenses	-	13.57	14.4	14.89	5.71

Updated Feb 26, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q